165 related articles for article (PubMed ID: 31157502)
1. Survival of children with endemic Burkitt lymphoma in a prospective clinical care project in Uganda.
McGoldrick SM; Mutyaba I; Adams SV; Larsen A; Krantz EM; Namirembe C; Mooka P; Nabakooza S; Ndagire M; Mubiru K; Nabwana M; Nankinga R; Gerdts S; Gordon-Maclean C; Geriga F; Omoding A; Sessle E; Kambugu J; Uldrick TS; Orem J; Casper C
Pediatr Blood Cancer; 2019 Sep; 66(9):e27813. PubMed ID: 31157502
[TBL] [Abstract][Full Text] [Related]
2. Outcome is unchanged by adding vincristine upfront to the Malawi 28-day protocol for endemic Burkitt lymphoma.
Depani S; Banda K; Bailey S; Israels T; Chagaluka G; Molyneux E
Pediatr Blood Cancer; 2015 Nov; 62(11):1929-34. PubMed ID: 26052841
[TBL] [Abstract][Full Text] [Related]
3. Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab.
Zhu KY; Song KW; Connors JM; Leitch H; Barnett MJ; Ramadan K; Slack GW; Abou Mourad Y; Forrest DL; Hogge DE; Nantel SH; Narayanan S; Nevill TJ; Power MM; Sanford DS; Sutherland HJ; Tucker T; Toze CL; Sehn LH; Broady R; Gerrie AS
Br J Haematol; 2018 Jun; 181(6):782-790. PubMed ID: 29741758
[TBL] [Abstract][Full Text] [Related]
4. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma.
Wang ES; Straus DJ; Teruya-Feldstein J; Qin J; Portlock C; Moskowitz C; Goy A; Hedrick E; Zelenetz AD; Noy A
Cancer; 2003 Sep; 98(6):1196-205. PubMed ID: 12973843
[TBL] [Abstract][Full Text] [Related]
5. Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study.
Galicier L; Fieschi C; Borie R; Meignin V; Daniel MT; Gérard L; Oksenhendler E
Blood; 2007 Oct; 110(8):2846-54. PubMed ID: 17609431
[TBL] [Abstract][Full Text] [Related]
6. A 5-drug regimen maximizing the dose of cyclophosphamide is effective therapy for adult Burkitt or Burkitt-like lymphomas.
Kujawski LA; Longo WL; Williams EC; Turman NJ; Brandt N; Mosher DF; Eickhoff JC; Kahl BS
Cancer Invest; 2007 Mar; 25(2):87-93. PubMed ID: 17453819
[TBL] [Abstract][Full Text] [Related]
7. The 2000 Burkitt lymphoma trial in Malawi.
Hesseling P; Broadhead R; Mansvelt E; Louw M; Wessels G; Borgstein E; Schneider J; Molyneux E
Pediatr Blood Cancer; 2005 Mar; 44(3):245-50. PubMed ID: 15547922
[TBL] [Abstract][Full Text] [Related]
8. Prospective study of Burkitt lymphoma treatment in adolescents and adults in Malawi.
Painschab MS; Westmoreland KD; Kasonkanji E; Zuze T; Kaimila B; Waswa P; El-Mallawany NK; Tomoka T; Mulenga M; Montgomery ND; Fedoriw Y; Gopal S
Blood Adv; 2019 Feb; 3(4):612-620. PubMed ID: 30796065
[TBL] [Abstract][Full Text] [Related]
9. Results of treatment with CMA, a low intermediate regimen, in endemic Burkitt lymphomas in sub-Saharian Africa: experience of Côte d'Ivoire.
Koffi GK; Tolo A; Nanho DC; N'dathz E; Kouassi MY; N'Diaye FD; Kouakou B; Meité N; Ayemou R; Sekongo M; Kouehion P; Meité M; Tea ND; Sangaré A; Sanogo I
Int J Hematol; 2010 Jun; 91(5):838-43. PubMed ID: 20480270
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of AIDS-related Burkitt lymphoma: a multi-institution retrospective survey in Japan.
Kojima Y; Hagiwara S; Uehira T; Ajisawa A; Kitanaka A; Tanuma J; Okada S; Nagai H
Jpn J Clin Oncol; 2014 Apr; 44(4):318-23. PubMed ID: 24558129
[TBL] [Abstract][Full Text] [Related]
11. Advanced Burkitt Lymphoma in Sub-Saharan Africa Pediatric Units: Results of the Third Prospective Multicenter Study of the Groupe Franco-Africain d'Oncologie Pédiatrique.
Bouda GC; Traoré F; Couitchere L; Raquin MA; Guedenon KM; Pondy A; Moreira C; Rakotomahefa M; Harif M; Patte C
J Glob Oncol; 2019 Nov; 5():1-9. PubMed ID: 31794283
[TBL] [Abstract][Full Text] [Related]
12. Outcomes for paediatric Burkitt lymphoma treated with anthracycline-based therapy in Malawi.
Stanley CC; Westmoreland KD; Heimlich BJ; El-Mallawany NK; Wasswa P; Mtete I; Butia M; Itimu S; Chasela M; Mtunda M; Chikasema M; Makwakwa V; Kaimila B; Kasonkanji E; Chimzimu F; Kampani C; Dhungel BM; Krysiak R; Montgomery ND; Fedoriw Y; Rosenberg NE; Liomba NG; Gopal S
Br J Haematol; 2016 Jun; 173(5):705-12. PubMed ID: 26914979
[TBL] [Abstract][Full Text] [Related]
13. Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma.
van Imhoff GW; van der Holt B; MacKenzie MA; Ossenkoppele GJ; Wijermans PW; Kramer MH; van 't Veer MB; Schouten HC; van Marwijk Kooy M; van Oers MH; Raemaekers JM; Sonneveld P; Meulendijks LA; Kluin PM; Kluin-Nelemans HC; Verdonck LF;
Leukemia; 2005 Jun; 19(6):945-52. PubMed ID: 15800666
[TBL] [Abstract][Full Text] [Related]
14. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.
Lim ST; Karim R; Nathwani BN; Tulpule A; Espina B; Levine AM
J Clin Oncol; 2005 Jul; 23(19):4430-8. PubMed ID: 15883411
[TBL] [Abstract][Full Text] [Related]
15. Five decades of low intensity and low survival: adapting intensified regimens to cure pediatric Burkitt lymphoma in Africa.
Ozuah NW; Lubega J; Allen CE; El-Mallawany NK
Blood Adv; 2020 Aug; 4(16):4007-4019. PubMed ID: 32841337
[TBL] [Abstract][Full Text] [Related]
16. Eighty-one percent event-free survival in advanced Burkitt's lymphoma/leukemia: no differences in outcome between pediatric and adult patients treated with the same intensive pediatric protocol.
Todeschini G; Tecchio C; Degani D; Meneghini V; Marradi P; Balter R; Zanotti R; Ricetti M; Franchini M; Perona G
Ann Oncol; 1997; 8 Suppl 1():77-81. PubMed ID: 9187436
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of biochemical markers in African Burkitt's lymphoma.
Arthur FK; Owusu L; Yeboah FA; Rettig T; Osei-Akoto A
Clin Transl Oncol; 2011 Oct; 13(10):731-6. PubMed ID: 21975335
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis.
Barnes JA; Lacasce AS; Feng Y; Toomey CE; Neuberg D; Michaelson JS; Hochberg EP; Abramson JS
Ann Oncol; 2011 Aug; 22(8):1859-64. PubMed ID: 21339382
[TBL] [Abstract][Full Text] [Related]
19. Optimal dosage of rituximab for children with Burkitt lymphoma.
Huang S; Jin L; Yang J; Zhang M; Zhang Y; Peng Y; Duan Y; Zheng H
Ann Hematol; 2024 Mar; 103(3):893-903. PubMed ID: 38091052
[TBL] [Abstract][Full Text] [Related]
20. Intensive, very short-term chemotherapy for advanced Burkitt's lymphoma in children.
Spreafico F; Massimino M; Luksch R; Casanova M; Cefalo GS; Collini P; Ferrari A; Polastri D; Terenziani M; Gasparini M; Fossati-Bellani F
J Clin Oncol; 2002 Jun; 20(12):2783-8. PubMed ID: 12065554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
